Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKC202 + limertinib versus osimertinib as first-line therapy for EGFR-mutant, MET-overexpressing advanced non-small cell lung cancer
CTR20263864Phase 3Active
- Sponsor
- Aosaikang Biotherapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of askc202, limertinib, osimertinib in non-small cell lung cancer (NSCLC), sponsored by Aosaikang Biotherapeutics. Started Oct 2026; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263864.